<div id="readability-page-1"><ul><li>Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut</li></ul><p>Eli Lilly and Company, AbbVie, Vertex Pharmaceuticals, Gilead Sciences, Pfizer, Abbott Laboratories,  and McKesson are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs and related healthcare products. For investors, they offer potential upside from successful drug approvals and patent-protected sales but also carry risks from long development cycles, regulatory hurdles, clinical-trial failures, and patent expirations. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most</li></ul><p>Read Our Latest Research Report on LLY</p><h2>AbbVie (ABBV)</h2><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><ul><li>The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles</li></ul><p>Read Our Latest Research Report on ABBV</p><h2>Vertex Pharmaceuticals (VRTX)</h2><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p><p>Read Our Latest Research Report on VRTX</p><h2>Gilead Sciences (GILD)</h2><p>Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.</p><p>Read Our Latest Research Report on GILD</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><p>Read Our Latest Research Report on PFE</p><h2>Abbott Laboratories (ABT)</h2><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p><p>Read Our Latest Research Report on ABT</p><h2>McKesson (MCK)</h2><p>McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.</p><p>Read Our Latest Research Report on MCK</p><h2>Featured Articles</h2><ul><li>MarketBeat's Top Five Stocks to Own in February 2026</li><li>Is LyondellBasell’s Nearly 10% Dividend Safe, or a Warning Sign for Investors?</li><li>Cybersecurity Demand Is High—Yet This ETF Is on Sale</li><li>3 Industrial Stocks Making New All-Time Highs</li><li>3 High-Growth Unknowns in Photonics That Are Vital for AI</li><li>MarketBeat Week in Review – 02/09 - 02/13</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VRTX

ABBV

<p>Eli Lilly, AbbVie, Vertex Pharmaceuticals, Gilead Sciences, Pfizer, Abbott Laboratories, and McKesson are highlighted as key pharmaceutical stocks to monitor, according to MarketBeat. These companies have shown significant trading volume recently and are involved in developing and selling various healthcare products. Investors should be aware of the potential risks and rewards associated with these stocks, including drug approvals and regulatory challenges.</p>

- Eli Lilly and Company, along with AbbVie, Vertex Pharmaceuticals, Gilead Sciences, Pfizer, Abbott Laboratories, and McKesson, are highlighted as top pharmaceutical stocks to watch due to high trading volumes.  
- These companies face potential risks from long drug development cycles and regulatory challenges, but they also offer opportunities from successful drug approvals.  
- MarketBeat notes that despite Eli Lilly's Moderate Buy rating, analysts recommend other stocks as better investment options at this time.

Best Pharmaceutical Stocks To Keep An Eye On - February 14th